A new alternative treatment for steatohepatitis has been developed; it consisits on new series of amides of fatty acids with fenilalquilamines (amphetamines, dopamine, etc.) A new mechanism of action based in reductions of consumption is exploded: activation of reduce intake and oxidative stress antagonism.
New and innovative aspects
The properties of the amides are: - PPAR alpha activation with major affinity to fibrates, what warrants deep lipid-lowering effects and metabolism activators. - Fatty liver deposit decrease. Inhibition of the SCD1 enzyme expression (desaturase 1), a fundamental mechanism in hepatic steatosis. -Capability of decrease the intake, thus antiobesity profile is added to its antiesteatosic profile.
Main advantages of its use
The benefits of its use are the following: - New therapeutic entities for one of the most prevalent metabolic diseases. - Small molecules easy to synthesize. - Its compounds are accepted by Lipinsky rule’s. - Safe Pharmacological profile not interact with hERG, and has no or moderate effects on the activity of various hepatic cytochrome P450.
In in vivo trials realized, both chronic and acute, have demonstrate evidence of activity against steatohepatitis, showing a decrease in liver level of plasma triglycerides. Furthermore, tests show renal functions improvement through a reduction in plasmatic levels of increased of urea and hepatic transaminase in plasma with a fall of ALT and AST
- Metabolic diseases and endocrinology
Current development status
In use, testing results avalaible
Desired business relationship